Literature DB >> 17669693

Who controls the placebo? Introducing a Placebo Quality Checklist for pharmacological trials.

Benno Brinkhaus1, Daniel Pach, Rainer Lüdtke, Stefan N Willich.   

Abstract

Randomised placebo-controlled trials (RCT) are an invaluable tool for testing the efficacy of new treatment strategies. The choice of placebo in an RCT can affect not only patients' physical and psychological response to a particular intervention, but also the trial setting, the success of patient blinding to the intervention, and therefore the outcome of the study and the efficacy of treatment in general. Therefore the placebo is intrinsically tied to the trial's methodology and results. However, although placebos are an important component in randomised trials, their quality is often left unquestioned. A placebo which was not properly validated may even have specific effects that lead to false negative results. To address this deficit, we propose a measure of placebo quality using the term placebo to assess the physical aspect of a dummy treatment used in the placebo group of a randomised controlled trial (RCT). The Placebo Quality Checklist (PQC) described here may help investigators select an appropriate placebo and help both investigators and critical readers interpret the findings of studies with more care.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17669693     DOI: 10.1016/j.cct.2007.06.005

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  9 in total

Review 1.  Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis.

Authors:  Winfried Rief; Yvonne Nestoriuc; Anna von Lilienfeld-Toal; Imis Dogan; Franziska Schreiber; Stefan G Hofmann; Arthur J Barsky; Jerry Avorn
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 2.  Characterization of the adverse events profile of placebo-treated patients in randomized controlled trials on drug-resistant focal epilepsies.

Authors:  Fabio Giovannelli; Gaetano Zaccara; Massimo Cincotta; Giulia Loiacono; Alberto Verrotti
Journal:  J Neurol       Date:  2014-10-14       Impact factor: 4.849

3.  A pre-trial evaluation of blinding for a Chinese herbal medicine trial.

Authors:  Shohreh Razavy; John Lee; Christopher Zaslawski
Journal:  Contemp Clin Trials Commun       Date:  2020-08-05

Review 4.  Adaption and application of the four phase trials to traditional chinese medicines.

Authors:  M Y Di; J L Tang
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-20       Impact factor: 2.629

5.  Efficacy and safety of Dingkun pill for female infertility patients with low prognosis undergoing in vitro fertilization-embryo transfer: study protocol for a multicenter, double-blind, randomized, placebo-controlled trial.

Authors:  Jingyan Song; Ting Ma; Yanlin Liang; Xianling Cao; Zhengao Sun
Journal:  Trials       Date:  2020-06-19       Impact factor: 2.279

6.  Placebo design in WHO-registered trials of Chinese herbal medicine need improvements.

Authors:  Xuan Zhang; Ran Tian; Chen Zhao; Xudong Tang; Aiping Lu; Zhaoxiang Bian
Journal:  BMC Complement Altern Med       Date:  2019-11-06       Impact factor: 3.659

7.  Visiting a sauna: does inhaling hot dry air reduce common cold symptoms? A randomised controlled trial.

Authors:  Daniel Pach; Bettina Knöchel; Rainer Lüdtke; Katja Wruck; Stefan N Willich; Claudia M Witt
Journal:  Med J Aust       Date:  2010 Dec 6-20       Impact factor: 7.738

8.  Developing Placebos for Clinical Research in Traditional Chinese Medicine: Assessing Organoleptic Properties of Three Dosage Forms (Oral Liquid, Capsule and Granule).

Authors:  Mengli Xiao; Jiake Ying; Yang Zhao; Qingna Li; Yingpan Zhao; Rui Gao; Fang Lu
Journal:  Front Pharmacol       Date:  2021-06-17       Impact factor: 5.810

9.  The Role of Traditional Chinese Formula Ding-Kun Pill (DKP) in Expected Poor Ovarian Response Women (POSEIDON Group 4) Undergoing In Vitro Fertilization-Embryo Transfer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Jing-Yan Song; Dan-Dan Gao; Xian-Ling Cao; Shan Xiang; Yan-Hua Chen; Yi-Li Teng; Xiu-Fang Li; Hai-Ping Liu; Fu-Xin Wang; Bin Zhang; Li-Hua Xu; Li Zhou; Xiang-Hong Huang; Zhen-Gao Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-17       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.